Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

dentsply sirona inc. - XRAY

XRAY

Close Chg Chg %
18.64 0.13 0.70%

Closed Market

18.77

+0.13 (0.70%)

Volume: 1.96M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: dentsply sirona inc. - XRAY

XRAY Key Data

Open

$18.60

 Day Range

18.60 - 18.87

52 Week Range

17.21 - 37.60

 Market Cap

$3.71B

Shares Outstanding

198.78M

 Public Float

197.58M

Beta

1.03

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.07

Yield

332.62%

 Dividend

$0.16

EX-DIVIDEND DATE

Sep 27, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

4.56M

  

XRAY Performance

1 Week
 
 1.97%
 
1 Month
 
 -20.03%
 
3 Months
 
 -26.35%
 
1 Year
 
 -40.49%
 
5 Years
 
 -67.45%
 

XRAY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About dentsply sirona inc. - XRAY

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

XRAY At a Glance

Dentsply Sirona, Inc.
13320 Ballantyne Corporate Place
Charlotte, North Carolina 28277-3607
Phone 1-844-848-0137 Revenue 3.97B
Industry Medical Specialties Net Income -132,000,000.00
Sector Health Technology 2023 Sales Growth 1.096%
Fiscal Year-end 12 / 2024 Employees 15,000
View SEC Filings

XRAY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.903
Price to Book Ratio 2.239
Price to Cash Flow Ratio 20.014
Enterprise Value to EBITDA 14.908
Enterprise Value to Sales 2.399
Total Debt to Enterprise Value 0.242

XRAY Efficiency

Revenue/Employee 264,333.333
Income Per Employee -8,800.00
Receivables Turnover 5.245
Total Asset Turnover 0.528

XRAY Liquidity

Current Ratio 1.385
Quick Ratio 0.947
Cash Ratio 0.234

XRAY Profitability

Gross Margin 52.686
Operating Margin 7.44
Pretax Margin -4.414
Net Margin -3.329
Return on Assets -1.758
Return on Equity -3.716
Return on Total Capital -2.361
Return on Invested Capital -2.40

XRAY Capital Structure

Total Debt to Total Equity 69.815
Total Debt to Total Capital 41.112
Total Debt to Total Assets 31.194
Long-Term Debt to Equity 58.336
Long-Term Debt to Total Capital 34.353
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dentsply Sirona Inc. - XRAY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
3.34B 4.23B 3.92B 3.96B
Sales Growth
-17.06% +26.60% -7.30% +1.10%
Cost of Goods Sold (COGS) incl D&A
1.65B 1.89B 1.79B 1.88B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
334.00M 346.00M 328.00M 343.00M
Depreciation
142.00M 124.00M 119.00M 132.00M
Amortization of Intangibles
192.00M 222.00M 209.00M 211.00M
COGS Growth
-11.69% +14.88% -5.29% +4.69%
Gross Income
1.70B 2.34B 2.13B 2.09B
Gross Income Growth
-21.68% +37.99% -8.94% -1.92%
Gross Profit Margin
+50.72% +55.28% +54.31% +52.69%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.42B 1.71B 1.76B 1.79B
Research & Development
115.00M 171.00M 174.00M 184.00M
Other SG&A
1.30B 1.54B 1.59B 1.61B
SGA Growth
-17.78% +20.54% +3.22% +1.76%
Other Operating Expense
- - - -
-
Unusual Expense
267.00M (12.00M) 1.27B 386.00M
EBIT after Unusual Expense
11.00M 643.00M (904.00M) (91.00M)
Non Operating Income/Expense
(9.00M) (32.00M) (101.00M) (20.00M)
Non-Operating Interest Income
- - - 1.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
62.00M 66.00M 50.00M 64.00M
Interest Expense Growth
+61.46% +6.45% -24.24% +28.00%
Gross Interest Expense
62.00M 66.00M 50.00M 64.00M
Interest Capitalized
- - - -
-
Pretax Income
(60.00M) 545.00M (1.05B) (175.00M)
Pretax Income Growth
-117.37% +1,008.33% -293.58% +83.41%
Pretax Margin
-1.80% +12.88% -26.90% -4.41%
Income Tax
23.00M 134.00M (105.00M) (43.00M)
Income Tax - Current - Domestic
(4.00M) 5.00M 5.00M 1.00M
Income Tax - Current - Foreign
91.00M 154.00M 118.00M 86.00M
Income Tax - Deferred - Domestic
(2.00M) 12.00M (162.00M) 1.00M
Income Tax - Deferred - Foreign
(62.00M) (37.00M) (66.00M) (131.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(83.00M) 411.00M (950.00M) (132.00M)
Minority Interest Expense
- - - -
-
Net Income
(83.00M) 411.00M (950.00M) (132.00M)
Net Income Growth
-131.57% +595.18% -331.14% +86.11%
Net Margin Growth
-2.48% +9.71% -24.22% -3.33%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(83.00M) 411.00M (950.00M) (132.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(83.00M) 411.00M (950.00M) (132.00M)
EPS (Basic)
-0.3786 1.8819 -4.4084 -0.6226
EPS (Basic) Growth
-132.13% +597.07% -334.25% +85.88%
Basic Shares Outstanding
219.20M 218.40M 215.50M 212.00M
EPS (Diluted)
-0.3786 1.8665 -4.4084 -0.6226
EPS (Diluted) Growth
-132.31% +593.00% -336.19% +85.88%
Diluted Shares Outstanding
219.20M 220.20M 215.50M 212.00M
EBITDA
612.00M 977.00M 695.00M 638.00M
EBITDA Growth
-19.83% +59.64% -28.86% -8.20%
EBITDA Margin
+18.31% +23.09% +17.72% +16.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 25.00
Number of Ratings 15 Current Quarters Estimate 0.447
FY Report Date 12 / 2024 Current Year's Estimate 1.855
Last Quarter’s Earnings 0.50 Median PE on CY Estimate N/A
Year Ago Earnings 1.83 Next Fiscal Year Estimate 1.945
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 10 12 12
Mean Estimate 0.45 0.43 1.85 1.94
High Estimates 0.63 0.50 2.03 2.26
Low Estimate 0.41 0.38 1.82 1.67
Coefficient of Variance 13.08 10.08 3.03 8.40

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 9 9
OVERWEIGHT 1 0 0
HOLD 7 7 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Dentsply Sirona Inc. - XRAY

Date Name Shares Transaction Value
Jul 16, 2024 Andrea L. Frohning SVP, CHRO 1,650 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Andreas G. Frank Exec VP/Chief Business Officer 7,865 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Andreas G. Frank Exec VP/Chief Business Officer 119,473 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Gregory T. Lucier Director 58,449 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Richard C. Rosenzweig SVP, Corp Dev, GC & Secretary 1,970 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Richard C. Rosenzweig SVP, Corp Dev, GC & Secretary 55,941 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Glenn G. Coleman Executive VP & CFO 1,880 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Brian T. Gladden Director 14,048 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Richard M. Wagner VP, Chief Accounting Officer 914 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Richard M. Wagner VP, Chief Accounting Officer 11,061 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Betsy DeHaas Holden Director 37,982 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Andrea L. Frohning SVP, CHRO 14,787 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Janet S. Vergis Director 29,898 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Willie A. Deese Director 43,144 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Leslie F. Varon Director 33,604 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Clyde R. Hosein Director 26,306 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Robert A. Johnson SVP, Chief Supply Chain Office 2,920 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Robert A. Johnson SVP, Chief Supply Chain Office 95,365 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Dorothea Wenzel Director 16,435 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 16, 2024 Glenn G. Coleman Executive VP & CFO 89,392 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Dentsply Sirona Inc. in the News